Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: A test-negative case-control study

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Helmeke, Carina ^a,b   Gräfe, Lutz ^b   Irmscher, Hanns Martin ^b   Gottschalk, Constanze ^b   Karagiannis, Ioannis ^a   Oppermann, Hanna ^b  

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^b State Institute for Consumer Protection of Saxony Anhalt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; LIVE VACCINE; VIRUS RNA;

ADOLESCENT; ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GERMANY; GROUPS BY AGE; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; VIRUS DETECTION; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; ODDS RATIO; PRESCHOOL CHILD; STANDARDS; STATISTICAL MODEL; TREATMENT OUTCOME;

INFLUENZA B VIRUS; ORTHOMYXOVIRIDAE;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; ODDS RATIO; RNA, VIRAL; TREATMENT OUTCOME; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84929459890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122910     Document Type: Article

References (39)

1. WHO: Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. February 2012. Available: http://www.who.int/influenza/vaccines/virus/recommendations/201202-recommendation.pdf
2. Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis. 2012; 31: 2549-2557. PMID: 22410646
3. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist; Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011; 71: 1591-1622. doi: 10.2165/11206860-000000000-00000 PMID: 21861544
4. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine. 2012; 30: 886-892. doi: 10.1016/j.vaccine.2011.11.104 PMID: 22155144
5. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis. 2012; 12: 36-44. doi: 10.1016/S1473-3099(11)70295-X PMID: 22032844
6. Block SL, Heikkinen T, Toback SL, Zheng W, Ambrose CS. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J. 2011; 30: 203-207. doi: 10.1097/INF.0b013e3181faac7c PMID: 20935591
7. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M et al. CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356: 685-696. PMID: 17301299
8. Ashkenazi S, Vertruyen A, Aristegui J Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006; 25: 870-879. PMID: 17006279
9. RKI: Mitteilung der Ständigen Impfkommission am Robert Koch-Institut (RKI). Empfehlungen der ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2013. Epid Bull. 2013; 34: 313-344.
10. Böhmer MM, Walter D, Falkenhorst G, Müters S, Krause G, Wichmann O. Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany. BMC Public Health. 2012 Oct 31; 12:938. doi: 10.1186/1471-2458-12-938 PMID: 23113995
11. RKI: Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI). Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen Influenza. Epid Bull. 2013; 36/37:365-370.
12. RIVM 2011: Influenza protocol PCR ErasmusMC. Available: http://www.rivm.nl/dsresource?objectid=rivmp:58725&type=org&disposition=inline&ns-nc=1
13. Weitzel T, Schnabel E, Dieckmann S, Börner U, Schweiger B. Evaluation of a new point-of-care test for influenza A and B virus in travellers with influenza-like symptoms. Clin Microbiol Infect. 2007; 13: 665-669. PMID: 17441977
14. Schulze M, Nitsche A, Schweiger B, Biere B. Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR. PLoS One. 2010 Apr 1; 5(4):e9966. doi: 10.1371/journal.pone.0009966 PMID: 20376359
15. RIVM: Laboratory Protocol Library. Influenza PCR. Updated June 2009.
16. Heim A, Ebnet C, Harste G, Pring-Akerblom P. (2003) Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol. 2003; 70: 228-239. PMID: 12696109
17. Burggraf S, Olgemöller B. Straightforward Procedure for Internal Control of Real-Time Reverse Transcription Amplification Assays. Clinical Chem. 2005; 51: 1508-1510. PMID: 16040843
18. Whiley DM, Syrmis MW, Mackay IM, Sloots TP. Detection of Human Respiratory Syncytial Virus in Respiratory Samples by LightCycler Reverse Transcriptase PCR. J Clin Microbiol. 2002; 40: 4418-4422. PMID: 12454129
19. Maertzdorf J, Wang CK, Brown JB, Quinto JD, Chu M, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol. 2004; 42: 981-986. PMID: 15004041
20. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004; 350: 443-450. PMID: 14749452
21. Deffernez C, Wunderli W, Thomas Y, Yerly S, Perrin L, Kaiser L. Amplicon Sequencing and Improved Detection of Human Rhinovirus in Respiratory Samples. J Clin Microbiol. 2004; 42: 3212-3218. PMID: 15243084
22. Mohamed N, Elfaitouri A, Fohlman J, Friman G, Blomberg J. A sensitive and quantitative single-tube real-time reverse transcriptase-PCR for detection of enteroviral RNA. J Clin Virol. 2004; 30: 150-156. PMID: 15125871
23. Monpoeho S, Dehée A, Mignotte B, Schwartzbrod L, Marechal V, Nicolas JC, et al. Quantification of Enterovirus RNA in Sludge Samples Using Single Tube Real-Time RT-PCR. BioTechniques. 2000; 29: 88-93. PMID: 10907082
24. ECDC: Protocol for case-control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States. Available: http://ecdc.europa.eu/en/publications/Publications/0907-TED-Influenza-AH1N1-Measuring-Influenza-Vaccine-Effectiveness-Protocol-case-Control-Studies.pdf
25. Valenciano M, Kissling E, Ciancio BC, Moren A. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine. 2010; 28: 7381-7388. doi: 10.1016/j.vaccine.2010.09.010 PMID: 20851086
26. Uphoff H, An der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, et al. Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009 - a comparison of two methods; Germany, 2009/10. PLoS One. 2011; 6(7):e19932. doi: 10.1371/journal.pone.0019932 PMID: 21789163
27. ECDC: Surveillance report. Influenza virus characterisation. Summary Europe, July 2013. Available: http://www.ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-July-2013.pdf
28. RKI: Arbeitsgemeinschaft Influenza: Bericht zur Epidemiologie der Influenza in Deutschland Saison 2012/13. Available: http://influenza.rki.de/Saisonberichte/2012.pdf
29. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014 Feb 13; 19(6). pii: 20701. PMID: 24556348
30. Snacken R, Broberg E, Beauté J, Lozano JE, Zucs P, Amato-Gauci AJ. Influenza season 2012-2013 in Europe: moderate intensity, mixed (sub)types. Epidemiol Infect. 2014; 142: 1809-1812. doi: 10.1017/S0950268814001228 PMID: 24814635
31. Belshe RB, Toback SL, Yi T, Ambrose CS. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respir Viruses. 2010; 4: 141-145. doi: 10.1111/j.1750-2659.2009.00124.x PMID: 20409210
32. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J: 2006; 25: 860-869. PMID: 17006278
33. Phillips CJ, Woolpert T, Sevick C, Faix D, Blair PJ, Crum-Cianflone NF. Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US military service members, 2006-2009. Clin Infect Dis. 2013; 56: 11-19. doi: 10.1093/cid/cis860 PMID: 23183869
34. Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, et al. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis. 2014; 14: 40. doi: 10.1186/1471-2334-14-40 PMID: 24450996
35. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006; 194: 1032-1039. PMID: 16991077
36. Allison MA, Daley MF, Crane LA, Barrow J, Beaty BL, Allred N, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr. 2006; 149: 755-762. PMID: 17137887
37. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics. 2005; 116: 153-159. PMID: 15995046
38. Eisenberg KW, Szilagyi PG, Fairbrother G, Griffin MR, Staat M, Shone LP, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics.2008; 122: 911-919. doi: 10.1542/peds.2007-3304 PMID: 18977968
39. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children. N Engl J Med.1998; 338: 1405-1412. PMID: 9580647